The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. On that note, here is one stock with the fundamentals to back up its performance and two best left ignored.
Two Stocks to Sell:
Vishay Intertechnology (VSH)
One-Month Return: +70.6%
Named after the founder's ancestral village in present-day Lithuania, Vishay Intertechnology (NYSE: VSH) manufactures simple chips and electronic components that are building blocks of virtually all types of electronic devices.
Why Should You Dump VSH?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 1.3% annually over the last two years
- Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 51.9% annually
- Increased cash burn over the last five years raises questions about the return timeline for its investments
Vishay Intertechnology is trading at $47.37 per share, or 1.6x forward price-to-sales. Read our free research report to see why you should think twice about including VSH in your portfolio.
Bristol-Myers Squibb (BMY)
One-Month Return: +2.8%
With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE: BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.
Why Are We Cautious About BMY?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
- Estimated sales decline of 3.4% for the next 12 months implies an even more challenging demand environment
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 1.7% annually while its revenue grew
Bristol-Myers Squibb’s stock price of $59.40 implies a valuation ratio of 9.7x forward P/E. If you’re considering BMY for your portfolio, see our FREE research report to learn more.
One Stock to Watch:
Coca-Cola (KO)
One-Month Return: +8.1%
A pioneer and behemoth in carbonated soft drinks, Coca-Cola (NYSE: KO) is a storied beverage company best known for its flagship soda.
Why Should KO Be on Your Watchlist?
- Unique products and pricing power are reflected in its best-in-class gross margin of 61.4%
- Healthy operating margin of 27% shows it’s a well-run company with efficient processes, and its profits increased over the last year as it scaled
- Free cash flow margin expanded by 27.5 percentage points over the last year, providing additional flexibility for investments and share buybacks/dividends
At $81.58 per share, Coca-Cola trades at 24.6x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
